SciELO - Scientific Electronic Library Online

 
vol.20 número4Methylation analysis of the CDKN2B and DBC1 tumour suppressor genes in leukaemia patients in ColombiaProductividad científica de las líneas de investigación y su contribución para el control del cáncer en Colombia: Scientific production of the research lines and its contribution for the control of cancer in Colombia índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Revista Colombiana de Cancerología

versão impressa ISSN 0123-9015

Resumo

RAMOS-PENAFIEL, Christian Omar et al. Prognostic factors of remission in patients with acute lymphoblastic leukemia after a first relapse. rev.colomb.cancerol. [online]. 2016, vol.20, n.4, pp.159-166. ISSN 0123-9015.  https://doi.org/10.1016/j.rccan.2016.11.001.

Aims: To identify those factors that affect therapeutic response to achieve a second remission (2 RC) in patients with acute lymphoblastic leukaemia (ALL) in relapse. Methods: Observational, descriptive and analytical study nested in a retrospective cohort of adults (> 18 years-old) ALL carriers treated during the period from 2008 to 2014 that disrupted the HGMLAL07 protocol when relapse was detected and began another therapeutic scheme. Results: The study included 69 patients, of whom 62.3% (n = 43) were males, and the mean age was 29 years-old. The therapeutic regimens used were: high intensity (55.1%) [Hyper-CVAD (n = 34), IDA-Flag (n = 1), mitoxantrone-DARAC (n = 3) ], moderate intensity (4.3%) [Re-induction schemes (n = 3) ], and palliative treatment of low intensity with transfusion support (40.6%, n = 28).Only 19 patients (27.5%) achieved a 2 RC. The median overall survival was 120 (2-575) days, 29% of patients were alive at one year. Using a high or moderate intensity regime as the rescue scheme gave no advantage over the conservative one (log-rank test, P = .812). None of the variables showed prognostic value of survival at one year. The duration of the first RC (OR 6.78, P = .005, 95% CI; 1.75 -26.28) and receiving high intensity treatment (OR 0.22, P = 018, 95% CI: 0.06 -0.78) were predictors of treatment failure to achieve 2 RC. Conclusions: To achieve a first RC < 1 year was an important risk factor for not achieving a 2 RC. No prognostic factors for survival were identified. None of the schemes used for rescue showed superiority.

Palavras-chave : Precursor Cell Lymphoblastic Leukaemia-Lymphoma; Risk Factors; Remission Induction; Survival; Anti-neoplastic Combined Chemotherapy Protocols.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )